Download PDF
Semin Respir Crit Care Med 2002; 23(4): 387-398
DOI: 10.1055/s-2002-34353
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Steroid-Unresponsive Asthma

Donald Y.M. Leung, Joseph D. Spahn, Stanley J. Szefler
  • Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado, and Department of Pediatrics and Pharmacology, University of Colorado Health Sciences Center; Denver, Colorado
Further Information

Publication History

Publication Date:
26 September 2002 (online)

    Permissions and Reprints

ABSTRACT

Although most patients with chronic asthma respond to corticosteroid therapy, a small subset of asthmatics are unresponsive to corticosteroids and demonstrate persistent airway obstruction and inflammation despite treatment with high doses of systemic glucocorticoids. There are at least two types of steroid-resistant asthma. Type I steroid-resistant (SR) asthma is cytokine induced and is associated with increased expression of glucocorticoid receptor beta, a less active glucocorticoid receptor isoform. Type II SR asthma is due to low numbers of glucocorticoid receptors. An important distinction between these two types of SR asthma is that the glucocorticoid receptor defect in Type I, but not Type II, SR asthma is reversible in culture and is sustained by incubation with combination interleukin (IL)-2 and IL-4. The treatment of these patients requires a systematic approach to rule out underlying conditions that lead to steroid resistance or treatment failure as well as the use of alternative strategies to inhibit airway inflammation

KEYWORDS

Asthma - steroid-resistant asthma - glucocorticoid - T cells

REFERENCES

  • 1 Lee T H, Brattsand R, Leung D YM. Corticosteroid action and resistance in asthma.  Am J Respir Cell Mol Biol . 1996;  154(suppl) S1-S79
    PubMedGoogle Scholar
  • 2 Schwartz H J, Lowell F C, Melby J C. Steroid resistance in bronchial asthma.  Ann Intern Med . 1968;  69 493-499
    PubMedGoogle Scholar
  • 3 Carmichael J, Paterson I C, Diaz P, Crompton G K, Kay A B, Grant I W. Corticosteroid resistance in chronic asthma.  Br Med J (Clin Res Ed) . 1981;  282 1419-1422
    PubMedGoogle Scholar
  • 4 Corrigan C J, Brown P H, Barnes N C. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro.  Am Rev Respir Dis . 1991;  144 1016-1025
    PubMedGoogle Scholar
  • 5 Kamada A K, Leung D YM, Gleason M C, Hill M R, Szefler S J. High-dose systemic glucocorticoid therapy in the treatment of severe asthma: a case of resistance and patterns of response.  J Allergy Clin Immunol . 1992;  90(4 Pt 1) 685-687
    CrossrefPubMedGoogle Scholar
  • 6 Corrigan C J, Brown P H, Barnes N C, Tsai J J, Frew A J, Kay A B. Glucocorticoid resistance in chronic asthma: peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A.  Am Rev Respir Dis . 1991;  144 1026-1032
    PubMedGoogle Scholar
  • 7 Alvarez J, Surs W, Leung D YM, Iklé D, Gelfand E W, Szefler S J. Steroid-resistant asthma: immunologic and pharmacologic features.  J Allergy Clin Immunol . 1992;  89 714-721
    PubMedGoogle Scholar
  • 8 Leung D YM, Martin R J, Szefler S J. Dysregulation of interleukin-4, interleukin-5, and interferon gamma gene expression in steroid-resistant asthma.  J Exp Med . 1995;  181 33-40
    CrossrefPubMedGoogle Scholar
  • 9 Bloom J W. Molecular mechanisms of glucocorticoid action. In: Szefler SJ, Leung DYM, eds. Severe Asthma: Pathogenesis and Clinical Management. New York: Marcel Dekker; 2001;167-194. Lefant C, ed. Lung Biology in Health and Disease Series, vol 159
    Google Scholar
  • 10 Auphan N, DiDonato J A, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.  Science . 1995;  270 286-290
    CrossrefPubMedGoogle Scholar
  • 11 John M, Lim S, Seybold J. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma.  Am J Respir Crit Care Med . 1998;  157 256-262
    PubMedGoogle Scholar
  • 12 Yang-Yen H F, Chambard J C, Sun Y L. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein- protein interaction.  Cell . 1990;  62 1205-1215
    CrossrefPubMedGoogle Scholar
  • 13 Schule R, Rangarajan P, Kliewer S. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor.  Cell . 1990;  62 1217-1226
    CrossrefPubMedGoogle Scholar
  • 14 Chrousos G P, Detera-Wadleigh S D, Karl M. Syndromes of glucocorticoid resistance.  Ann Intern Med . 1993;  119 1113-1124
    PubMedGoogle Scholar
  • 15 Sher E R, Leung D YM, Surs W. Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy.  J Clin Invest . 1994;  93 33-39
    PubMedGoogle Scholar
  • 16 Kam J C, Szefler S J, Surs W, Sher E R, Leung D YM. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids.  J Immunol . 1993;  151 3460-3466
    PubMedGoogle Scholar
  • 17 Spahn J D, Szefler S J, Surs W, Doherty D E, Nimmagadda S R, Leung D YM. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity.  J Immunol . 1996;  157 2654-2659
    PubMedGoogle Scholar
  • 18 Burchard E G, Silverman E K, Rosenwasser L J. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma.  Am J Respir Crit Care Med . 1999;  160 919-922
    PubMedGoogle Scholar
  • 19 Rosa-Rosa L, Zimmermann N, Bernstein J A, Rothenberg M E, Khurana Hershey K G. The R576 IL-4 receptor alpha allele correlates with asthma severity.  J Allergy Clin Immunol . 1999;  104 1008-1014
    PubMedGoogle Scholar
  • 20 Rosenwasser L J, Klemm J D, Klemm D J, Drazen J M, Burchard E G, Leung D YM. Association of asthmatic steroid insensitivity with an Il-4 gene promoter polymorphism.  J Allergy Clin Immunol . 2001;  107(pt.2) 771A
    PubMedGoogle Scholar
  • 21 Spahn J D, Brown E E, Covar R, Leung D YM. Do African-Americans display a diminished response to glucocorticoids (GCs)?.  J Allergy Clin Immunol . 1999;  103(1, pt.2) S62 #238A
    PubMedGoogle Scholar
  • 22 Chan M T, Leung D YM, Szefler S J, Spahn J D. Difficult-to-control asthma: clinical characteristics of steroid- insensitive asthma.  J Allergy Clin Immunol . 1998;  101 594-601
    PubMedGoogle Scholar
  • 23 Barnes P J, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.  N Engl J Med . 1997;  336 1066-1071
    CrossrefPubMedGoogle Scholar
  • 24 Adcock I M, Lane S J, Brown C R, Peters M J, Lee T H, Barnes P J. Differences in binding of glucocorticoid receptor to DNA in steroid- resistant asthma.  J Immunol . 1995;  154 3500-3505
    PubMedGoogle Scholar
  • 25 Lane S J, Adcock I M, Richards D, Hawrylowicz C, Barnes P J, Lee T H. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes.  J Clin Invest . 1998;  102 2156-2164
    PubMedGoogle Scholar
  • 26 Vottero A, Chrousos G P. Glucocorticoid receptor beta: view I.  Trends Endocrinol Metab . 1999;  10 333-338
    PubMedGoogle Scholar
  • 27 Bamberger C M, Bamberger A M, de Castro M, Chrousos G P. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans.  J Clin Invest . 1995;  95 2435-2441
    PubMedGoogle Scholar
  • 28 Oakley R H, Sar M, Cidlowski J A. The human glucocorticoid receptor beta isoform: expression, biochemical properties, and putative function.  J Biol Chem . 1996;  271 9550-9559
    CrossrefPubMedGoogle Scholar
  • 29 Oakley R H, Jewell C M, Yudt M R, Bofetiado D M, Cidlowski J A. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action.  J Biol Chem . 1999;  274 27857-27866
    CrossrefPubMedGoogle Scholar
  • 30 Bamberger C M, Else T, Bamberger A M, Beil F U, Schulte H M. Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor.  Mol Cell Endocrinol . 1997;  136 23-28
    PubMedGoogle Scholar
  • 31 Strickland I, Kisich K, Hauk P J. High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids.  J Exp Med . 2001;  193 585-594
    CrossrefPubMedGoogle Scholar
  • 32 Leung D YM, Hamid Q, Vottero A. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta.  J Exp Med . 1997;  186 1567-1574
    CrossrefPubMedGoogle Scholar
  • 33 Hamid Q A, Wenzel S E, Hauk P J. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma.  Am J Respir Crit Care Med . 1999;  159(5 Pt 1) 1600-1604
    PubMedGoogle Scholar
  • 34 Otto C, Reichardt H M, Schutz G. Absence of glucocorticoid receptor-beta in mice.  J Biol Chem . 1997;  272 26665-26668
    CrossrefPubMedGoogle Scholar
  • 35 Sousa A R, Lane S J, Soh C, Lee T H. In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation.  J Allergy Clin Immunol . 1999;  104(3 Pt 1) 565-574
    PubMedGoogle Scholar
  • 36 Nimmagadda S R, Szefler S J, Spahn J D, Surs W, Leung D YM. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics.  Am J Respir Crit Care Med . 1997;  155 87-93
    PubMedGoogle Scholar
  • 37 Hauk P J, Wenzel S E, Trumble A E, Szefler S J, Leung D YM. Increased T cell receptor vbeta8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: a potential role for microbial superantigens.  J Allergy Clin Immunol . 1999;  104 37-45
    PubMedGoogle Scholar
  • 38 Kotzin B L, Leung D YM, Kappler J, Marrack P. Superantigens and their potential role in human disease.  Adv Immunol . 1993;  5499-166
    PubMedGoogle Scholar
  • 39 Hauk P J, Hamid Q A, Chrousos G P, Leung D YM. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens.  J Allergy Clin Immunol . 2000;  105 782-787
    CrossrefPubMedGoogle Scholar
  • 40 Wenzel S E, Szefler S J, Leung D YM, Sloan S I, Rex M D, Martin R J. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids.  Am J Respir Crit Care Med . 1997;  156(3 Pt 1) 737-743
    PubMedGoogle Scholar
  • 41 Kraft M, Vianna E, Martin R J, Leung D YM. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night.  J Allergy Clin Immunol . 1999;  103(1 Pt 1) 66-71
    PubMedGoogle Scholar
  • 42 Kraft M, Hamid Q, Martin R J, Leung D YM. Glucocorticoid receptor-beta is associated with reduced steroid responsiveness at night in nocturnal asthma.  Am J Respir Crit Care Med . 2001;  163 1219-1225
    PubMedGoogle Scholar
  • 43 Christodoulopoulos P, Leung D YM, Elliott M W. Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma.  J Allergy Clin Immunol . 2000;  106 479-484
    CrossrefPubMedGoogle Scholar
  • 44 Leung D YM, Spahn J D, Szefler S J. Steroid-resistant asthma: new insights and implications for management. In: Szefler SJ, Leung DYM, eds. Severe Asthma: A Multidisciplinary Approach 2nd ed. New York: Marcel Dekker 2001: 597-620
    Google Scholar
  • 45 Buske-Kirschbaum A, Jobst S, Psych D. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis.  Psychosom Med . 1997;  59 419-426
    PubMedGoogle Scholar
  • 46 Murray A B, Ferguson A C, Morrison B J. The frequency and severity of cat allergy vs dog allergy in atopic children.  J Allergy Clin Immunol . 1983;  72 145-149
    CrossrefPubMedGoogle Scholar
  • 47 Perzanowski M S, Ronmark E, Nold B, Lundback B, Platts-Mills T A. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure.  J Allergy Clin Immunol . 1999;  103 1018-1024
    PubMedGoogle Scholar
  • 48 Kraft M, Cassell G H, Henson J E. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma.  Am J Respir Crit Care Med . 1998;  158 998-1001
    PubMedGoogle Scholar
  • 49 Martin R J, Kraft M, Chu H W, Berns E A, Cassell G H. A link between chronic asthma and chronic infection.  J Allergy Clin Immunol . 2001;  107 595-601
    CrossrefPubMedGoogle Scholar
  • 50 Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma.  BMJ . 2000;  320 1368-1373
    CrossrefPubMedGoogle Scholar
  • 51 Eickelberg O, Roth M, Lorx R. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells.  J Biol Chem . 1999;  274 1005-1010
    CrossrefPubMedGoogle Scholar
  • 52 Tamaoki J, Kondo M, Sakai N. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group.  Am J Respir Crit Care Med . 1997;  155 1235-1240
    PubMedGoogle Scholar
  • 53 Robinson D S, Campbell D, Barnes P J. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial.  Lancet. . 2001;  357 2007-2011
    CrossrefPubMedGoogle Scholar
  • 54 Nelson H S. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.  J Allergy Clin Immunol . 2001;  107 398-416
    CrossrefPubMedGoogle Scholar
  • 55 Martin R J, Cicutto L C, Ballard R D, Goldenheim P D, Cherniack R M. Circadian variations in theophylline concentrations and the treatment of nocturnal asthma.  Am Rev Respir Dis . 1989;  139 475-478
    PubMedGoogle Scholar
  • 56 Spahn J D, Landwehr L P, Nimmagadda S, Surs W, Leung D YM, Szefler S J. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma.  J Allergy Clin Immunol . 1996;  98(6 Pt 1) 1073-1079
    PubMedGoogle Scholar
  • 57 Thorsson L, Edsbacker S, Conradson T B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.  Eur Respir J . 1994;  7 1839-1844
    CrossrefPubMedGoogle Scholar
  • 58 Seale J P, Harrison L I. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics.  Respir Med . 1998;  9-15 (9-15)
    PubMedGoogle Scholar
  • 59 Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner J O. Treatment of severe steroid dependent preschool asthma with nebulized budesonide suspension.  Arch Dis Child . 1993;  68 356-359
    PubMedGoogle Scholar
  • 60 Hill M R, Szefler S J, Ball B D, Bartoszek M, Brenner A M. Monitoring glucocorticoid therapy: a pharmacokinetic approach.  Clin Pharmacol Ther . 1990;  48 390-398
    PubMedGoogle Scholar
  • 61 Kamada A K, Spahn J D, Surs W, Brown E, Leung D YM, Szefler S J. Coexistence of glucocorticoid receptor and pharmacokinetic abnormalities: factors that contribute to a poor response to treatment with glucocorticoids in children with asthma.  J Pediatr . 1994;  124 984-986
    PubMedGoogle Scholar
  • 62 Ledford D, Apter A, Brenner A M. Osteoporosis in the corticosteroid-treated patient with asthma.  J Allergy Clin Immunol . 1998;  102 353-362
    PubMedGoogle Scholar
  • 63 Vignola A M, Chanez P, Bousquet J. Management of severe asthma. In: Szefler SJ, Leung DYM, eds. Severe Asthma: Pathogenesis and Clinical Management New York: Marcel Dekker; 2001;575-596. Lefant C, ed. Lung Biology in Health and Disease Series, vol 159
    Google Scholar
  • 64 Spahn J D, Leung D YM, Chan M T, Szefler S J, Gelfand E W. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin.  J Allergy Clin Immunol . 1999;  103(3 Pt 1) 421-426
    PubMedGoogle Scholar
  • 65 Redington A E, Hardinge F M, Madden J, Holgate S T, Howarth P H. Cyclosporin A treatment and airways inflammation in corticosteroid-dependent asthma.  Allergy . 1998;  53 94-98
    PubMedGoogle Scholar
  • 66 Vrugt B, Wilson S, van Velzen E. Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients.  Thorax . 1997;  52 662-664
    PubMedGoogle Scholar
  • 67 Molet S, Hamid Q A. Role of airway remodeling in severe asthma. In: Szefler SJ, Leung DYM, eds. Severe Asthma: Pathogenesis and Clinical Management New York: Marcel Dekker; 2001;89-124. Lefant C, ed. Lung Biology in Health and Disease Series, vol 159
    Google Scholar
  • 68 Busse W, Corren J, Lanier B Q. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.  J Allergy Clin Immunol . 2001;  108 184-190
    CrossrefPubMedGoogle Scholar
  • 69 Broide D H. Molecular and cellular mechanisms of allergic disease.  J Allergy Clin Immunol . 2001;  108 S65-S71
    CrossrefPubMedGoogle Scholar
  • 70 Wamboldt F S, Spahn J D, Klinnert M D. Clinical outcomes of steroid insensitive asthma.  Ann Allergy Asthma Immunol . 1999;  83 55-60
    PubMedGoogle Scholar
      >